1. Dermatology Partnering Terms and Agreements
Report Details:
Published:October 2012
No. of Pages: 942
Price: Single User License – US$2695
The Dermatology Partnering Terms and Agreements report provides a detailed understanding and
analysis of how and why companies enter dermatology partnering deals. The majority of deals are
discovery, preclinical or development stage whereby the licensee obtains a right or an option right
to license the licensors bacterials technology. These deals tend to be multicomponent, starting
with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest dermatology deals and contracts announced in the
healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered – contract documents
provide this insight where press releases and databases do not.
The report includes an analysis of financial deal terms by stage at signing covering headline value,
upfront payment, milestone payments and royalty rates. The initial chapters of this report provide
an orientation of dermatology dealmaking and business activities. Chapter 1 provides an
introduction to the report.
Chapter 2 provides an overview of the trends in dermatology dealmaking since 2007 covering
trends by year, deal type, stage of development, technology type and therapeutic indication. In
addition the chapter includes an analysis of financial deal terms by stage at signing covering
headline value, upfront payment, milestone payments and royalty rates. Analysis includes median
values and distribution of values for each stage of development.
Chapter 3 provides a review of the leading dermatology deals since 2007. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.

2. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief
summary followed by a comprehensive listing of dermatology deals, as well as contract
documents available in the public domain. Where available, each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each contract document
on demand.
Chapter 5 provides comprehensive access to all dermatology deals since 2007 where a deal
contract is available, providing the user with direct access to contracts as filed with the SEC
regulatory authorities. Each deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all dermatology partnering deals signed and
announced since 2007. The chapter is organized by specific dermatology therapy focus. Each
deal title links via Weblink to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all dermatology partnering
deals signed and announced since 2007. The appendices are organized by company A-Z, stage
of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in
dermatology partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about
partnering in the research, development and commercialization of dermatology technologies and
products.
Key benefits
Dermatology Partnering Terms and Agreementsprovides the reader with the following key
benefits:
•In-depth understanding of dental deal trends since 2007
•Access dental deal headline, upfront, milestone and royalty data
•Research hundreds of actual contracts between dermatology partner companies
•Comprehensive access to over 1500 links to actual dermatology deals entered into by the world’s
biopharma companies
•Indepth review of dental deals entered into by the leading fifty bigpharma companies
•Benchmark the key deal terms companies have agreed in previous deals
•Identify key terms under which companies partner dermatology opportunities

3. •Uncover companies actively partnering dermatology opportunities
Report scope
Dermatology Partnering Terms and Agreements is intended to provide the reader with an in-depth
understanding and access to dermatology trends and structure of deals entered into by leading
companies worldwide.
Dermatology Partnering Terms and Agreements includes:
•Trends in dermatology dealmaking in the biopharma industry since 2007
•Analysis of dermatology deal structure
•Access to headline, upfront, milestone and royalty data
•Access to hundreds of dermatology deal contract documents
•Comprehensive access to over 1500 dermatology deal records
•The leading dermatology deals by value since 2007
•Most active dermatology dealmakers since 2007
In Dermatology Partnering Terms and Agreements, available deals and contracts are listed by:
•Headline value o Upfront payment value
•Royalty rate value o Stage of development at signing
•Deal component type
•Technology type
•Specific therapy indication
Get your copy of this report @
http://www.reportsnreports.com/reports/199945-dermatology-partnering-terms-and-agreements.html
Major points covered in Table of Contents of this report include
Table of contents
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in dermatology dealmaking
2.1. Introduction
2.2. Dermatology partnering over the years
2.3. Bigpharma dermatology dealmaking activity
2.4. Bigpharma not active in dermatology
2.5. Dermatology partnering by deal type
2.6. Dermatology partnering by industry sector
2.7. Dermatology partnering by stage of development
2.8. Dermatology partnering by technology type
2.9. Dermatology partnering by dermatology indication

4. 2.10. Average deal terms for dermatology
2.10.1 Dermatology headline values
2.10.2 Dermatology upfront payments
2.10.3 Dermatology milestone payments
2.10.4 Dermatology royalty rates
Chapter 3 – Leading dermatology deals
3.1. Introduction
3.2. Top dermatology deals by value
3.3. Top dermatology deals involving bigpharma
Chapter 4 – Bigpharma dermatology deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma dermatology partnering company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bristol-Myers
Squibb C
elgene
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
GlaxoSmithKline
Hospira
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Pfizer
Roche
Sanofi
Shionogi

5. Shire
Teva
Warner Chilcott
Watson
Chapter 5 – Dermatology partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Joint venture
Licensing
Litigation
Loan
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
5.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
5.4. By technology type
Antibodies

6. Assays
Biologicalcompounds
Biomaterials
Clinical testing
Devices
Diagnostics
DNA probes
Drug delivery
Enabling technology
Equipment
Genomics
Natural product
Oligonucleotide
Orphan drug
Peptides
Processes
Recombinant DNA
Regenerative medicine
Research services
Research supplies
Screening
Small molecules
Stem cells
Chapter 6 – Dermatology dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Dermatology
Acne
Actinickeratosis
Angioedema
Burns
Cellulitis
Cosmetics
Dermatitis
Diabetic foot ulcer
Eczema Hair disorders
Impetigo
Itching
Nail disorders
Psoriasis Rosacea
Sun damage

7. Rash Scar
Venous ulcer
Wound healing
Wrinkles
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Directory of dermatology deals by company A-Z 2007-2012
Appendix 2 – Directory of dermatology deals by deal type 2007-2012
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out

8. Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 3 - Directory of dermatology deals by stage of development 2007-2012
Appendix 4 – Directory of dermatology deals by technology type 2007
Appendix 5 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
List of Figures
Figure 1: Dermatology partnering since 2007
Figure 2: Bigpharma – top 50 – dermatology deals 2007 to 2012
Figure 3: Bigpharma dermatology deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in dermatology 2007-2012
Figure 5: Dermatology partnering by deal type since 2007
Figure 6: Dermatology partnering by industry sector since 2007
Figure 7: Dermatology partnering by stage of development since 2007
Figure 8: Dermatology partnering by technology type since 2007
Figure 9: Dermatology partnering by dermatology target since 2007
Figure 10: Dermatology deals with a headline value
Figure 11: Dermatology deal headline value distribution, US$million – discovery stage
Figure 12: Dermatology deal headline value distribution, US$million – preclinical stage
Figure 13: Dermatology deal headline value distribution, US$million – phase I stage
Figure 14: Dermatology deal headline value distribution, US$million – phase II stage
Figure 15: Dermatology deal headline value distribution, US$million – phase III stage
Figure 16: Dermatology deal headline value distribution, US$million – regulatory stage
Figure 17: Dermatology deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2012
Figure 19 Dermatology deals with upfront payment values
Figure 20: Dermatology deal upfront payment distribution, US$million – discovery stage
Figure 21: Dermatology deal upfront payment distribution, US$million – preclinical stage
Figure 22: Dermatology deal upfront payment distribution, US$million – phase I stage
Figure 23: Dermatology deal upfront payment distribution, US$million – phase II stage
Figure 24: Dermatology deal upfront payment distribution, US$million – phase III stage
Figure 25: Dermatology deal upfront payment distribution, US$million – regulatory stage

9. Figure 26: Dermatology deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2012
Figure 28: Dermatology deals with milestone payments
Figure 29: Dermatology deal milestone distribution, US$million – discovery stage
Figure 30: Dermatology deal milestone distribution, US$million – preclinical stage
Figure 31: Dermatology deal milestone distribution, US$million – phase I stage
Figure 32: Dermatology deal milestone distribution, US$million – phase II stage
Figure 33: Dermatology deal milestone distribution, US$million – phase III stage
Figure 34: Dermatology deal milestone distribution, US$million – regulatory stage
Figure 35: Dermatology deal milestone distribution, US$million – marketed stage 94
Figure 36: Dermatology deals with royalty rates, %
Figure 37: Dermatology deal royalty rate distribution, US$million – discovery stage
Figure 38: Dermatology deal royalty rate distribution, US$million – preclinical stage
Figure 39: Dermatology deal royalty rate distribution, US$million – phase I stage
Figure 40: Dermatology deal royalty rate distribution, US$million – phase II stage
Figure 41: Dermatology deal royalty rate distribution, US$million – phase III stage
Figure 42: Dermatology deal royalty rate distribution, US$million – regulatory stage
Figure 43: Summary median royalty rate by stage of development, 2007-2012
Figure 44: Top dermatology deals by value since 2007
Figure 45: Top dermatology deals signed by bigpharma value since 2007
Figure 46: Online partnering resources Figure
47: Forthcoming partnering events
Contact: sales@reportsandreports.com for more information.